Does the Mounjaro Injection Make You Tired?

Fatigue is a recognised side effect of tirzepatide, recorded in clinical trials and listed in the medicine's patient information leaflet.
It most often peaks in the first 24–48 hours after an injection, particularly when starting treatment or moving to a higher dose.
Reduced calorie intake alongside treatment can contribute; staying hydrated and eating enough protein helps many people.
Tiredness that is severe, does not settle, or comes with other symptoms should always be discussed with your prescriber or a doctor.

Fatigue after a Mounjaro injection is real, and fairly common — but it is rarely the whole story. Tiredness appears in the clinical trial data as a reported side effect, listed on the NHS tirzepatide page alongside the better-known gastrointestinal symptoms. For most people who notice it, the feeling is mild and tends to cluster in the first day or two after each pen, especially early in treatment or following a dose increase. It does not mean something has gone wrong, and it does not usually last. Because tirzepatide is a prescription-only medicine, your prescriber is the right person to judge whether tiredness you are experiencing fits the expected pattern or needs a closer look.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What the evidence says — and how to tell normal from notable

The misconception worth clearing up first

A lot of people assume the tiredness they feel on Mounjaro is proof that the medicine is "draining" them, or that their body is rejecting it. That framing is understandable but not quite right. What is actually happening, for most people, is a predictable physiological response to a medicine that slows gastric emptying, shifts appetite signalling, and (in the early weeks) prompts the body to adjust to meaningful changes in food intake and metabolic rhythm. The fatigue is a passenger in that adjustment, not a warning light.

That said, dismissing it entirely would also be wrong. Tiredness is a real symptom that deserves a clear answer, not reassurance dressed up as information. So here is what the evidence actually shows, and what to watch for.

You can read more about how the medicine acts on two separate gut-hormone receptors on our page covering how the Mounjaro injection works.

Why tiredness happens, and when it tends to peak

Tirzepatide activates both GIP and GLP-1 receptors involved in appetite regulation and blood-sugar control. As the body adapts, GI symptoms (nausea, indigestion, sometimes loose stools) are the most commonly reported side effects, but fatigue and headache follow close behind in the clinical data. The NHS lists tiredness explicitly among the common side effects of tirzepatide.

In practice, many people find the fatigue is sharpest on the day after their injection, a pattern our prescribers hear about regularly. If you are finding that timing particularly noticeable, the day-after tiredness page looks at that window in detail. The likely reasons include the mild nausea-driven dip in food intake, the body's metabolic recalibration, and, for some, mild dehydration from any GI side effects. None of those are dangerous in themselves. All of them tend to ease as the weeks pass.

Starting at 2.5mg (the lowest strength) is partly about tolerability. The first pen's job is to let your system adjust before the prescriber considers moving upward; the tiredness, where it appears, is usually mildest at this stage. Each dose increase can briefly revive the feeling, then it settles again.

Factors that can make tiredness worse, and practical things that help

Eating significantly less than usual is almost certain on Mounjaro, because appetite suppression is central to how it works. But a sharp drop in overall calorie intake, without keeping protein and hydration up, can leave people feeling flat in ways that compound any medicine-related fatigue. This is not unique to tirzepatide; it happens with calorie restriction generally.

A few things consistently come up in clinical guidance as worth prioritising: adequate protein at each meal (to preserve lean mass and sustain energy), consistent hydration throughout the day, and not skipping meals entirely even when appetite is low. Strength-based activity, where tolerated, also helps preserve the muscle mass that energy levels depend on. None of this is complicated, but a dietitian or your prescriber can give advice shaped to your specific situation.

Injection site and technique are less likely to affect tiredness directly, though correct rotation does reduce localised reactions. Our guide to injection sites covers that in full. If you are finding injections themselves uncomfortable, this page addresses that separately.

For a broader picture of the treatment (including how it is prescribed privately) see our Mounjaro injection overview.

When to stop waiting and speak to someone

The MHRA, which oversees medicines safety in the UK, monitors tirzepatide under its Black Triangle scheme, meaning any unusual or unexpected effects are tracked carefully. Fatigue that is mild and tied to the first day or two after each pen sits well within the expected range. The following patterns are different, and worth raising promptly with your prescriber or a doctor:

Tiredness that does not improve after the first few weeks at a given dose; fatigue accompanied by severe or persistent stomach pain (especially pain reaching toward the back); significant dizziness or feeling faint; any symptoms suggesting dehydration after a bout of vomiting or diarrhoea. You can report any suspected side effect directly through the MHRA Yellow Card scheme.

If you have questions about your treatment and are already a patient with us, our aftercare team is available seven days a week. If you are still considering whether this treatment is right for you, a free consultation with one of our GPhC-registered prescribers is the logical starting point. A real clinician reviews every application (not software) and will consider your full health picture before any prescription is issued.

You can find an overview of all the weight-loss treatments we prescribe on our weight-loss treatment page, or go straight to the consultation hub to start your free assessment.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions